I am a
Home I AM A Search Login

Papers of the Week

Papers: 21 Oct 2023 - 27 Oct 2023

2023 Oct 18

N Engl J Med


Teplizumab and β-Cell Function in Newly Diagnosed Type 1 Diabetes.


Ramos EL, Dayan CM, Chatenoud L, Sumnik Z, Simmons KM, Szypowska A, Gitelman SE, Knecht LA, Niemoeller E, Tian W, Herold KC


Teplizumab, a humanized monoclonal antibody to CD3 on T cells, is approved by the Food and Drug Administration to delay the onset of clinical type 1 diabetes (stage 3) in patients 8 years of age or older with preclinical (stage 2) disease. Whether treatment with intravenous teplizumab in patients with newly diagnosed type 1 diabetes can prevent disease progression is unknown.